I
Immunome
Immunome - Novel Immunotherapies for Cancer
About Immunome
Immunome is a biotechnology company focused on developing first-in-class therapeutics by harnessing the power of the immune system. The company operates in the biopharmaceutical market and serves clients in the healthcare and medical research sectors. Immunome's proprietary discovery platform identifies novel therapeutic antibodies and their targets by analyzing the immune systems of patients who have successfully fought off diseases. This approach aims to create groundbreaking treatments for various conditions. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potential future sales of approved therapies. Immunome's team includes experts in clinical oncology and medical research, ensuring a strong foundation for scientific innovation.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2008
- Headquarters
- Bothell, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- EAEvolution Corporate Advisors
Series B and later2 investors entered at this stage
BioAdvance- RVRobin Hood Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
13 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunome on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunome on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.